Literature DB >> 8962095

Peptides containing glutamine repeats as substrates for transglutaminase-catalyzed cross-linking: relevance to diseases of the nervous system.

P Kahlem1, C Terré, H Green, P Djian.   

Abstract

Many proteins contain reiterated glutamine residues, but polyglutamine of excessive length may result in human disease by conferring new properties on the protein containing it. One established property of a glutamine residue, depending on the nature of the flanking residues, is its ability to act as an amine acceptor in a transglutaminase-catalyzed reaction and to make a glutamyl-lysine cross-link with a neighboring polypeptide. To learn whether glutamine repeats can act as amine acceptors, we have made peptides with variable lengths of polyglutamine flanked by the adjacent amino acid residues in the proteins associated with spinocerebellar ataxia type 1 (SCA1), Machado-Joseph disease (SCA3), or dentato-rubral pallidoluysian atrophy (DRPLA) or those residues adjacent to the preferred cross-linking site of involucrin, or solely by arginine residues. The polyglutamine was found to confer excellent substrate properties on any soluble peptide; under optimal conditions, virtually all the glutamine residues acted as amine acceptors in the reaction with glycine ethyl-ester, and lengthening the sequence of polyglutamine increased the reactivity of each glutamine residue. In the presence of transglutaminase, peptides containing polyglutamine formed insoluble aggregates with the proteins of brain extracts and these aggregates contained glutamyl-lysine cross-links. Repeated glutamine residues exposed on the surface of a neuronal protein should form cross-linked aggregates in the presence of any transglutaminase activated by the presence of Ca2+.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8962095      PMCID: PMC26176          DOI: 10.1073/pnas.93.25.14580

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  42 in total

1.  Factors that govern the specificity of transglutaminase-catalysed modification of proteins and peptides.

Authors:  P J Coussons; N C Price; S M Kelly; B Smith; L Sawyer
Journal:  Biochem J       Date:  1992-03-15       Impact factor: 3.857

Review 2.  Genetics and molecular biology of Huntington's disease.

Authors:  R L Albin; D A Tagle
Journal:  Trends Neurosci       Date:  1995-01       Impact factor: 13.837

3.  Determination of protein-bound glutamine.

Authors:  H Toda; J E Folk
Journal:  Biochim Biophys Acta       Date:  1969-03

4.  Codon reiteration and the evolution of proteins.

Authors:  H Green; N Wang
Journal:  Proc Natl Acad Sci U S A       Date:  1994-05-10       Impact factor: 11.205

5.  Codon repeats in genes associated with human diseases: fewer repeats in the genes of nonhuman primates and nucleotide substitutions concentrated at the sites of reiteration.

Authors:  P Djian; J M Hancock; H S Chana
Journal:  Proc Natl Acad Sci U S A       Date:  1996-01-09       Impact factor: 11.205

6.  Structure and expression of the Huntington's disease gene: evidence against simple inactivation due to an expanded CAG repeat.

Authors:  Christine M Ambrose; Mabel P Duyao; Glenn Barnes; Gillian P Bates; Carol S Lin; Jayalakshmi Srinidhi; Sarah Baxendale; Holger Hummerich; Hans Lehrach; Michael Altherr; John Wasmuth; Alan Buckler; Deanna Church; David Housman; Mary Berks; Gos Micklem; Richard Durbin; Alan Dodge; Andrew Read; James Gusella; Marcy E MacDonald
Journal:  Somat Cell Mol Genet       Date:  1994-01

7.  Identification of Gln726 in nidogen as the amine acceptor in transglutaminase-catalyzed cross-linking of laminin-nidogen complexes.

Authors:  D Aeschlimann; M Paulsson; K Mann
Journal:  J Biol Chem       Date:  1992-06-05       Impact factor: 5.157

8.  Structural features of glutamine substrates for transglutaminases. Role of extended interactions in the specificity of human plasma factor XIIIa and of the guinea pig liver enzyme.

Authors:  J J Gorman; J E Folk
Journal:  J Biol Chem       Date:  1984-07-25       Impact factor: 5.157

9.  Labeling of epsilon-lysine crosslinking sites in proteins with peptide substrates of factor XIIIa and transglutaminase.

Authors:  K N Parameswaran; P T Velasco; J Wilson; L Lorand
Journal:  Proc Natl Acad Sci U S A       Date:  1990-11       Impact factor: 11.205

10.  Covalent modification of synapsin I by a tetanus toxin-activated transglutaminase.

Authors:  F Facchiano; F Benfenati; F Valtorta; A Luini
Journal:  J Biol Chem       Date:  1993-03-05       Impact factor: 5.157

View more
  43 in total

1.  Increased T-type Ca2+ channel activity as a determinant of cellular toxicity in neuronal cell lines expressing polyglutamine-expanded human androgen receptors.

Authors:  A Sculptoreanu; H Abramovici; A A Abdullah; A Bibikova; V Panet-Raymond; D Frankel; H M Schipper; L Pinsky; M A Trifiro
Journal:  Mol Cell Biochem       Date:  2000-01       Impact factor: 3.396

2.  Nuclear and neuropil aggregates in Huntington's disease: relationship to neuropathology.

Authors:  C A Gutekunst; S H Li; H Yi; J S Mulroy; S Kuemmerle; R Jones; D Rye; R J Ferrante; S M Hersch; X J Li
Journal:  J Neurosci       Date:  1999-04-01       Impact factor: 6.167

3.  Therapeutic effects of cystamine in a murine model of Huntington's disease.

Authors:  Alpaslan Dedeoglu; James K Kubilus; Thomas M Jeitner; Samantha A Matson; Misha Bogdanov; Neil W Kowall; Wayne R Matson; Arthur J L Cooper; Rajiv R Ratan; M Flint Beal; Steven M Hersch; Robert J Ferrante
Journal:  J Neurosci       Date:  2002-10-15       Impact factor: 6.167

Review 4.  Huntington's disease: a decade beyond gene discovery.

Authors:  Penelope Hogarth
Journal:  Curr Neurol Neurosci Rep       Date:  2003-07       Impact factor: 5.081

5.  Structural characterization of transglutaminase-catalyzed cross-linking between glyceraldehyde 3-phosphate dehydrogenase and polyglutamine repeats.

Authors:  Margherita Ruoppolo; Stefania Orrù; Simona Francese; Ivana Caputo; Carla Esposito
Journal:  Protein Sci       Date:  2003-01       Impact factor: 6.725

Review 6.  Engineered antibody therapies to counteract mutant huntingtin and related toxic intracellular proteins.

Authors:  David C Butler; Julie A McLear; Anne Messer
Journal:  Prog Neurobiol       Date:  2011-11-18       Impact factor: 11.685

7.  Modeling Huntington's disease in cells, flies, and mice.

Authors:  S Sipione; E Cattaneo
Journal:  Mol Neurobiol       Date:  2001-02       Impact factor: 5.590

Review 8.  Apoptotic cascades as possible targets for inhibiting cell death in Huntington's disease.

Authors:  Lindsay R Pattison; Mark R Kotter; Dean Fraga; Raphael M Bonelli
Journal:  J Neurol       Date:  2006-09-22       Impact factor: 4.849

Review 9.  Aggregation of expanded huntingtin in the brains of patients with Huntington disease.

Authors:  Guylaine Hoffner; Sylvie Souès; Philippe Djian
Journal:  Prion       Date:  2007 Jan-Mar       Impact factor: 3.931

10.  Method for screening and MALDI-TOF MS sequencing of encoded combinatorial libraries.

Authors:  Bi-Huang Hu; Marsha Ritter Jones; Phillip B Messersmith
Journal:  Anal Chem       Date:  2007-08-23       Impact factor: 6.986

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.